Lianhuan Pharmaceutical: LH-1801 project cannot obtain approval for listing in the short term, and there is significant uncertainty about whether it will be approved for listing in the future.

2026-04-02 23:50:59

Announcement of abnormal stock trading volatility by Lianhuan Pharmaceutical Co., Ltd. The Company has noticed relevant information in the market regarding the LH-1801 program. In the short term, the LH-1801 program cannot obtain approval for listing. There is significant uncertainty as to whether it can subsequently obtain approval for listing and the specific timeline after approval for listing. LH-1801 is an SGLT-2 inhibitor for the treatment of diabetes. There are currently about 8 products in the market for the treatment of type 2 diabetes. Even if LH-1801 is able to successfully obtain approval for listing in the future, it will still face substantial competition. Investors are kindly reminded to be aware of the risks of secondary-market trading, make rational decisions, and invest prudently.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.